Trump presidency could prove a salve for pharma merger deals – Reuters


Reuters

Trump presidency could prove a salve for pharma merger deals
Reuters
Despite a few headline-grabbing deals, such as Pfizer Inc’s (PFE.N) $14 billion acquisition of cancer drugmaker Medivation Inc in August, overall life sciences dealmaking is down 65 percent from the same period last year, according to Thomson Reuters data.

and more »

Read More…

Share This: